Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: Toronto

    A phase 3 rollover study of VX-659 triple combination drug in people 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (VX-659-105) , protocol number VX-659-105 NCT03447262

    CFTR function study evaluating the long term safety and efficacy of VX-659 combination therapy

    • Age:

      12+

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      96 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Vancouver, Montreal, Toronto

    A phase 3 study of tazacaftor (VX-661) combination drug in children aged 6 years and older (VX17-661-116) , protocol number VX17-661-116) NCT03537651

    CFTR function study, evaluating the safety and efficacy of long-term treatment with tezacaftor in combination with ivacaftor in subjects aged 6-11 years

    • Age:

      6+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      96 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Vancouver, Montreal, Toronto

    A phase 3 rollover study of VX-445 triple combination drug in people 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation (VX17-445-105) , protocol number VX17-445-105 NCT03525574

    CFTR function study, evaluating the long-term effectiveness, safety, and effect on the body of the drug VX-445 in combination with tezacaftor and ivacaftor

    • Age:

      12+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      One copy F508del

    • Number of Visits:

      Not specified

    • Length of Participation:

      96 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Toronto

    A phase 3 open-label extension study in people 12 years and older (VX-18-445-113) , protocol number VX 18-445-113 NCT04043806

    This study will evaluate the long term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA).

    • Age:

      12+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      100 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Montreal, Toronto and Vancouver

    A phase 3 rollover study evaluating the long-term safety and efficacy of VX-445 triple combination therapy (VX18-445-110) , protocol number VX-445-100 NCT04058366

    This study will evaluate the long-term safety, efficacy and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with texacaftor (TEX) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).

    • Age:

      12+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      96 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Vancouver & Toronto

    A phase 3 rollover study evaluating the long-term safety and efficacy of VX-445 combination therapy in subjects with cystic fibrosis who are 6 years of age and older (VX 18-445-107) , protocol number VX 18-445-107 NCT04183790

    This study will evaluate the long-term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF).

    • Age:

      6+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      96 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM)

    ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number NCT04294043 NCT04294043

    This study is taking place at multiple care centres across the U.S. It will look at the safety and tolerability IV gallium, a drug intended to treat infections in the lung.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% of greater

    • Number of Visits:

      8

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: Pennsylvania, USA

    Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (CX-280-202) , protocol number CX-280-202 NCT04279769

    This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      6

    • Length of Participation:

      2 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiples sites across the United States

    Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number ELX-02 Eloxx-EL-012

    This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      15

    • Length of Participation:

      15 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryRecruiting Location: Multiple centres across the US & Australia

    Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD) , protocol number Laurent LAU-14-01 NCT03265288

    An international Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Required

    • FEV1% Predicted:

      between 40% and 100%

    • Number of Visits:

      6

    • Length of Participation:

      189 days

    Contact us about this clinical Trial >
  • Displaying results 41-50 (of 225)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|